Drug intelligence / Profile preview

[11C] raclopride

Development stage
Phase 1
Lead developer
ABX
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[11C] raclopride is a radiolabeled form of the dopamine D2 receptor antagonist raclopride, in which the molecule is tagged with the radioactive isotope carbon-11. It acts as a selective antagonist at dopamine D2 receptors, with much lower affinity for D3 and negligible affinity for other dopamine receptor subtypes. The compound is primarily used as a positron emission tomography (PET) radiotracer to non-invasively image and quantify striatal dopamine D2 receptor availability in vivo. This allows assessment of dopaminergic function in neurological and psychiatric disorders such as Parkinson's disease, Huntington's disease, schizophrenia, major depressive disorder, and substance use disorders. The binding of [11C] raclopride can be displaced by endogenous dopamine or pharmacological agents that increase synaptic dopamine levels; thus it serves as an indirect marker for changes in extracellular dopamine concentrations during various tasks or drug challenges[2][3][4][5][6][8].

Other names
carbon-11 raclopridecarbon11 raclopridecarbon 11 raclopride[^11C]-raclopride
02

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on [11C] raclopride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C] raclopride.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call